Expanded Access Multicenter Study of Lucanix® (Belagenpumatucel-L)
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- NovaRx Corporation
- Registration Number
- NCT01279798
- Locations
- 🇺🇸
Innovative Research Center of California, San Diego, California, United States
Phase II Study of Lucanixâ„¢ in Patients With Stages II-IV Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung NeoplasmCarcinoma, Bronchogenic
- Interventions
- Biological: Lucanix
- First Posted Date
- 2010-01-29
- Last Posted Date
- 2010-07-29
- Lead Sponsor
- NovaRx Corporation
- Target Recruit Count
- 75
- Registration Number
- NCT01058785
- Locations
- 🇺🇸
Hoag Cancer Center, Newport Beach, California, United States
🇺🇸Mary Crowley Medical Research Center, Dallas, Texas, United States
🇺🇸Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD, and Janet Burroff MD APM, Metairie, Louisiana, United States
Phase III Lucanixâ„¢ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
Phase 3
Completed
- Conditions
- Carcinoma Non-small Cell Lung Cancer Stage IIIBCarcinoma Non-small Cell Lung Cancer Stage IVLung NeoplasmCarcinoma Non-small Cell Lung Cancer Stage IIIA
- Interventions
- Other: Placebo ComparatorBiological: Lucanixâ„¢
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2015-05-08
- Lead Sponsor
- NovaRx Corporation
- Target Recruit Count
- 532
- Registration Number
- NCT00676507
- Locations
- 🇵🇱
Centrum Onkologii - Instytut im.Marii Sklodowskiej-Curie, Warsaw, Poland
🇷🇸Klinicko-bolnicki centar Bezanijska kosa, Belgrade, Serbia
🇺🇸Comprehensive Blood and Cancer Center, Bakersfield, California, United States
© Copyright 2025. All Rights Reserved by MedPath